Jasper Therapeutics, Inc.
NASDAQ:JSPR
22.75 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.108 | 1.31 | 0.566 | 0.021 | 0 |
| Gross Profit
| -1.108 | -1.31 | -0.566 | -0.021 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 53.413 | 34.627 | 25.421 | 15.883 | 3.618 |
| General & Administrative Expenses
| 17.076 | 16.569 | 11.412 | 4.8 | 1.092 |
| Selling & Marketing Expenses
| -1.108 | 0 | 0 | 0 | 0 |
| SG&A
| 15.968 | 16.569 | 11.412 | 4.8 | 1.092 |
| Other Expenses
| 0 | 0.586 | -0.08 | -0.111 | 0 |
| Operating Expenses
| 69.381 | 51.196 | 36.833 | 20.683 | 4.454 |
| Operating Income
| -70.489 | -51.196 | -36.833 | -20.683 | -4.71 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.396 | 13.511 | 6.196 | -10.986 | -0.277 |
| Income Before Tax
| -66.093 | -37.685 | -30.637 | -31.669 | -4.987 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.628 | -13.511 | -6.653 | -0.038 | -0 |
| Net Income
| -64.465 | -24.174 | -23.984 | -31.669 | -4.987 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -6.18 | -6.63 | -21.05 | -114.3 | 0 |
| EPS Diluted
| -6.18 | -6.63 | -21.05 | -114.3 | 0 |
| EBITDA
| -69.381 | -64.121 | -43.109 | -9.808 | -0.277 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |